Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Impact of Mindfulness Intervention on Quality of Life in Patients With Drug-resistant Epilepsy. [NA]
A clinical trial evaluating mindfulness to improve quality of life in patients with drug-resistant epilepsy is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: TDCs to Treat Drug-resistant Epilepsy [NA]
Clinical trial update notes completion of a study evaluating TDCs for drug-resistant epilepsy.
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Intracerebral Electrical Stimulation and the Optimisation of Presurgical Planning in Drug-refractory Partial Epilepsy [NA]
This clinical trial from University Hospital, Toulouse investigates intracerebral electrical stimulation to optimize presurgical planning fo…
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: Sensor-Dot and Plug 'n Patch Study in Epilepsy [NA]
The trial evaluating Sensor-Dot and Plug 'n Patch for epilepsy has completed.
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Integrative and Complementary Health Practices (PICS) [NA]
Clinical trial update for Integrative and Complementary Health Practices (PICS) shows a study currently recruiting for neoplasms and epileps…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-05-06FDA Approved: CLOBAZAM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for CLOBAZAM (clobazam) submitted by Micro Labs Limited.
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy [Phase 1]
A Phase 1 study of RLS103 in a clinical model of photosensitive epilepsy was terminated; the trial aimed to evaluate safety, tolerability, a…
-
CLINICAL_TRIALS research · 2024-05-02Clinical Trial Update: An Automated Navigation System for Deep Brain Electrode Implantation
A clinical trial is evaluating an automated navigation system for deep brain electrode implantation in Parkinson's disease, epilepsy, and ob…
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Analysis of Electrocorticographic Signals [NA]
A completed clinical trial analyzed electrocorticographic signals in epilepsy patients; results were posted in May 2024.
-
CLINICAL_TRIALS research · 2024-04-29Clinical Trial Update: The Effect of the Training Programme Based on the Health Promotion Model Given to Parents [NA]
This document updates on a clinical trial evaluating a training program based on the Health Promotion Model for parents of children with epi…
-
CLINICAL_TRIALS research · 2024-04-26Clinical Trial Update: Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy [Phase 1]
A Phase 1 trial is evaluating leucine-enriched essential amino acid powder added to a classic ketogenic diet for refractory epilepsy and dru…
-
FDA approval · 2024-04-25FDA Approved: DIAZEPAM — Original Application (Alembic Pharmaceuticals Limited)
FDA approves Alembic Pharmaceuticals Limited's original application for a generic diazepam product. This approval supports a generic version…
-
FDA approval · 2024-04-24FDA Approved: LACOSAMIDE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for lacosamide submitted by Ascend Laboratories, LLC, signaling a regulatory action on this generic …
-
CLINICAL_TRIALS trial_result · 2024-04-24Clinical Trial Update: An Investigation of Levetiracetam in Alzheimer's Disease [Phase 2]
Phase 2 clinical trial investigating levetiracetam in Alzheimer's disease has completed.
-
FDA approval · 2024-04-23FDA Approved: LEVETIRACETAM — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for levetiracetam submitted by Apotex Corp., under ANDA 202958.
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 [Phase 2]
Phase 2 trial update evaluating safety, tolerability, and pharmacokinetics of intravenous SPM 927 in epilepsy has completed.
-
FDA approval · 2024-04-15FDA Approved: LAMOTRIGINE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for lamotrigine from Ajanta Pharma USA Inc.
-
FDA approval · 2024-04-11FDA Approved: LAMOTRIGINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves Glenmark's supplemental application for lamotrigine (ANDA 079099), resulting in an approved change to the lamotrigine product u…
-
FDA approval · 2024-04-08FDA Approved: GABAPENTIN — Original Application (Laurus Labs Limited)
FDA approved Laurus Labs Limited's Original Application for gabapentin, permitting the marketing of a generic gabapentin product.
-
FDA approval · 2024-04-05FDA Approved: XCOPRI — Supplemental Application (SK Life Science, Inc.)
The FDA granted a supplemental approval for XCOPRI (cenobamate) from SK Life Science, Inc.
-
FDA approval · 2024-04-02FDA Approved: LACOSAMIDE — Original Application (Kanchan Healthcare Inc)
FDA approved an Original Application for Lacosamide by Kanchan Healthcare Inc, authorizing a generic lacosamide product (ANDA 218014) for us…
-
FDA approval · 2024-03-27FDA Approved: ESLICARBAZEPINE ACETATE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin's generic eslicarbazepine acetate (original application) for use in treating partial-onset seizures in adults.
-
FDA approval · 2024-03-25FDA Approved: LACOSAMIDE — Original Application (Dr. Reddy's Laboratories Inc.)
FDA approved Dr. Reddy's Laboratories' Original Application for lacosamide (LACOSAMIDE) as a generic anticonvulsant.
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: Fecal Microbiota Transplantation for Epilepsy [Phase 2, Phase 3]
A clinical trial update on fecal microbiota transplantation for epilepsy, spanning Phase 2 and Phase 3.
-
FDA approval · 2024-03-18FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie Inc.